Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - March 2013


18th Congress of The European Association of Hospital Pharmacists (EAHP)

13 Mar 2013 - 15 Mar 2013 - Palais des Congrès, Paris, France



Bookmark and Share


The European Association of Hospital Pharmacists (EAHP) is a working community of national associations of hospital pharmacists. Membership is increasing each year and, at present, EAHP represents the interest of over 21,000 hospital pharmacists in 32 countries all over Europe.

EAHP’s annual congress is the largest congress for hospital pharmacy in Europe and is attended by professionals from over 50 countries. Approximately 4.000 hospital pharmacists are expected to attend the 18th Congress of the EAHP next 13-15 March 2013 at the Palais des Congrès in Paris, France.

“Improving patient outcomes – a shared responsibility”  will be the theme for the presentations at the Paris 2013 EAHP Congress. A scientific programme including 3 keynote presentations, 13 seminars open for interactions with the speakers and 3 interactive workshops will offer participants the unique opportunity to meet, network and share expertise. EAHP’s industry partners have also committed to conducting satellite symposia highlighting important new developments important to hospital pharmacy.

EAHP’s Congress is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education, as well as by some of its national member associations according to the different national accreditation systems.

REGISTRATION OPEN 1 AUGUST 2012:
Register online to attend the EAHP 18th Congress.

CALL FOR ABSTRACTS: 
Deadline for submission is 15 October 2012.  Original contributions from all fields of hospital pharmacy are welcomed for poster presentation. 

For further information, please visit the website, where you will also be able to find more details on our scientific programme.

The registration fees are set follows :

 

— before 1 December 2012  € 600

— beginning 1 December 2012 € 700

— beginning 1 February 2013 € 800

 

Registration fee includes access to all sessions, the opening reception, the exhibition, lunches on Wednesday, Thursday, Friday and coffee/tea during official breaks.

 

Registration fee includes 19,6% VAT until 1 October and 21,2% afterwards according to French law.



Further information
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!